Recommended

Discover how to overcome low affinity or poor TCR yields that are slowing you down in this upcoming webinar – register your details today
WEBINAR | Discover how advances can expand the possibilities for drug discovery, from target validation to preclinical development
Facing roadblocks in obesity drug discovery? Discover how integrated, validated strategies are helping teams accelerate development and reduce risk – register your details now
Unlock the science, strategy and real-world impact behind the next generation of precision therapies – access our new brand report now >>
Safety data is no longer just a regulatory checkbox – it’s a strategic advantage. Find out more in our upcoming webinar, register your details today
Explore how AI is reshaping early drug discovery, from target identification and compound screening to predictive modelling and trial design – register now!

List view / Grid view

Hit-to-Lead

 

news

Nosopharm joins ENABLE to help combat antibiotic resistance

7 December 2015 | By Victoria White

The €100m ENABLE project aims to identify at least three antibacterial lead molecules with promising antibacterial activity, two antibacterial clinical candidate molecules and to enter at least one compound into preclinical and Phase 1 clinical studies...

ProteinSimple MFI 5000 Series
ProteinSimple MFI 5000 Series
product

ProteinSimple MFI 5000 Series

4 December 2015 | By ProteinSimple

Address the US FDA requirement to characterize and quantify protein aggregates and other particle contaminants sized 1-70 microns in biotherapeutics...

DTR Issue 4 2015
DTR Issue 4 2015
article

Drug Target Review – Issue #4 2015

3 December 2015 | By Drug Target Review

Included in this issue: Biomarkers, Mass Spectrometry, Target Validation, Drug Development, Personalised Medicines, Next-Generation Sequencing, Protein Expression, Companion Diagnostics, and much more...

Mass Spectrometry In-Depth Focus 2015
Mass Spectrometry In-Depth Focus 2015
article

Mass Spectrometry In-Depth Focus 2015

3 December 2015 | By , , , ,

In this Mass Spectrometry In-Depth Focus: Michelle M. Hill from University of Queensland discusses Mass spectrometric and systems biology approaches in drug target discovery, and Nicola Burgess-Brown, Rod Chalk, Claire Strain-Damerell and Pravin Mahajan from the Structural Genomics Consortium look at analysing recombinant proteins by mass spectrometry...

Biomarkers as molecular footprints for cancer therapy
Biomarkers as molecular footprints for cancer therapy
article

Biomarkers as molecular footprints for cancer therapy: current perspectives and promises

3 December 2015 | By , , ,

Knowledge about cancer biomarkers has increased tremendously and provides clinicians and researchers with valued opportunities to understand the molecular mechanism of cancer, thus applying it to effective, early-stage diagnosis and treatment. Cancer biomarkers include a vast range of biochemical molecules such as nucleic acids, proteins, sugars, lipids, small metabolites, cytogenetic…